JNETS clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms: diagnosis, treatment, and follow-up: a synopsis

JNETS clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms: diagnosis, treatment, and follow-up: a synopsis. Ito, T., Masui, T., Komoto, I., Doi, R., Osamura, R. Y., Sakurai, A., Ikeda, M., Takano, K., Igarashi, H., Shimatsu, A., Nakamura, K., Nakamoto, Y., Hijioka, S., Morita, K., Ishikawa, Y., Ohike, N., Kasajima, A., Kushima, R., Kojima, M., Sasano, H., Hirano, S., Mizuno, N., Aoki, T., Aoki, T., Ohtsuka, T., Okumura, T., Kimura, Y., Kudo, A., Konishi, T., Matsumoto, I., Kobayashi, N., Fujimori, N., Honma, Y., Morizane, C., Uchino, S., Horiuchi, K., Yamasaki, M., Matsubayashi, J., Sato, Y., Sekiguchi, M., Abe, S., Okusaka, T., Kida, M., Kimura, W., Tanaka, M., Majima, Y., Jensen, R. T., Hirata, K., Imamura, M., & Uemoto, S. Journal of Gastroenterology, 56(11):1033–1044, November, 2021.
doi abstract bibtex

Neuroendocrine neoplasms (NENs) are rare neoplasms that occur in various organs and present with diverse clinical manifestations. Pathological classification is important in the diagnosis of NENs. Treatment strategies must be selected according to the status of differentiation and malignancy by accurately determining whether the neoplasm is functioning or nonfunctioning, degree of disease progression, and presence of metastasis. The newly revised Clinical Practice Guidelines for Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs) comprises 5 chapters-diagnosis, pathology, surgical treatment, medical and multidisciplinary treatment, and multiple endocrine neoplasia type 1 (MEN1)/von Hippel-Lindau (VHL) disease-and includes 51 clinical questions and 19 columns. These guidelines aim to provide direction and practical clinical content for the management of GEP-NEN preferentially based on clinically useful reports. These revised guidelines also refer to the new concept of "neuroendocrine tumor" (NET) grade 3, which is based on the 2017 and 2019 WHO criteria; this includes health insurance coverage of somatostatin receptor scintigraphy for NEN, everolimus for lung and gastrointestinal NET, and lanreotide for GEP-NET. The guidelines also newly refer to the diagnosis, treatment, and surveillance of NEN associated with VHL disease and MEN1. The accuracy of these guidelines has been improved by examining and adopting new evidence obtained after the first edition was published.

@article{ito_jnets_2021,
	title = {{JNETS} clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms: diagnosis, treatment, and follow-up: a synopsis},
	volume = {56},
	issn = {1435-5922},
	shorttitle = {{JNETS} clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms},
	doi = {10.1007/s00535-021-01827-7},
	abstract = {Neuroendocrine neoplasms (NENs) are rare neoplasms that occur in various organs and present with diverse clinical manifestations. Pathological classification is important in the diagnosis of NENs. Treatment strategies must be selected according to the status of differentiation and malignancy by accurately determining whether the neoplasm is functioning or nonfunctioning, degree of disease progression, and presence of metastasis. The newly revised Clinical Practice Guidelines for Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs) comprises 5 chapters-diagnosis, pathology, surgical treatment, medical and multidisciplinary treatment, and multiple endocrine neoplasia type 1 (MEN1)/von Hippel-Lindau (VHL) disease-and includes 51 clinical questions and 19 columns. These guidelines aim to provide direction and practical clinical content for the management of GEP-NEN preferentially based on clinically useful reports. These revised guidelines also refer to the new concept of "neuroendocrine tumor" (NET) grade 3, which is based on the 2017 and 2019 WHO criteria; this includes health insurance coverage of somatostatin receptor scintigraphy for NEN, everolimus for lung and gastrointestinal NET, and lanreotide for GEP-NET. The guidelines also newly refer to the diagnosis, treatment, and surveillance of NEN associated with VHL disease and MEN1. The accuracy of these guidelines has been improved by examining and adopting new evidence obtained after the first edition was published.},
	language = {eng},
	number = {11},
	journal = {Journal of Gastroenterology},
	author = {Ito, Tetsuhide and Masui, Toshihiko and Komoto, Izumi and Doi, Ryuichiro and Osamura, Robert Y. and Sakurai, Akihiro and Ikeda, Masafumi and Takano, Koji and Igarashi, Hisato and Shimatsu, Akira and Nakamura, Kazuhiko and Nakamoto, Yuji and Hijioka, Susumu and Morita, Koji and Ishikawa, Yuichi and Ohike, Nobuyuki and Kasajima, Atsuko and Kushima, Ryoji and Kojima, Motohiro and Sasano, Hironobu and Hirano, Satoshi and Mizuno, Nobumasa and Aoki, Taku and Aoki, Takeshi and Ohtsuka, Takao and Okumura, Tomoyuki and Kimura, Yasutoshi and Kudo, Atsushi and Konishi, Tsuyoshi and Matsumoto, Ippei and Kobayashi, Noritoshi and Fujimori, Nao and Honma, Yoshitaka and Morizane, Chigusa and Uchino, Shinya and Horiuchi, Kiyomi and Yamasaki, Masanori and Matsubayashi, Jun and Sato, Yuichi and Sekiguchi, Masau and Abe, Shinichi and Okusaka, Takuji and Kida, Mitsuhiro and Kimura, Wataru and Tanaka, Masao and Majima, Yoshiyuki and Jensen, Robert T. and Hirata, Koichi and Imamura, Masayuki and Uemoto, Shinji},
	month = nov,
	year = {2021},
	pmid = {34586495},
	pmcid = {PMC8531106},
	keywords = {Aftercare, Clinical practice guideline, Gastroenteropancreatic neuroendocrine neoplasm, Guidelines as Topic, Humans, Intestinal Neoplasms, Japanese Neuroendocrine Tumor Society, Neuroendocrine Tumors, Pancreatic Neoplasms, Stomach Neoplasms},
	pages = {1033--1044},
}

Downloads: 0